7 results
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... TZDs DPP-4 inhibitors ... #medications #table ... comparison #management #endocrinology
Summary of Non-Insulin Agents Used to Treat Diabetes

#Diabetes #Pharmacology #Comparison #Table #Medications #Noninsulin #Orals #Agents
Summary of Non-Insulin ... Agents Used to ... #Diabetes #Pharmacology ... #Comparison #Table ... #Medications #Noninsulin
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
Summary of dosing ... hypoglycaemic agents ... #Diabetes #Diabetic ... #Medications #Pharmacology ... Impairment #CKD #Table
Comparison of anti-diabetic or anti-hyperglycemic agents

There are numerous anti-hyperglycemic agents available to manage Type 2 diabetes.
Each class of medications ... #pharmacology #pharmacotherapy ... #table #comparison ... #management #medications ... #diabetes #endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
- Pharmacology ... Summary Mechanisms ... #Inhibitors #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Type 2 Inpatient Medication ... Sulfonylurea, TZD, DPP ... #pharmacology # ... comparison #table ... #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
drug to remain stable ... empagliflozin and DPP4 ... #semaglutide #Diabetes ... #Pharmacology # ... Endocrinology